^
    Back
    Association details:
    Biomarker:miR-211 expression
    Cancer:Melanoma
    Drug:Cotellic (cobimetinib) (MEK1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    J Invest Dermatol
    Title:

    MicroRNA-211 modulates the DUSP6-ERK5 signaling axis to promote BRAF V600E-driven melanoma growth in vivo and BRAF/MEK inhibitor resistance

    Published date:
    09/01/2020
    Excerpt:
    We therefore examined whether miR-211 similarly modulated melanoma resistance to the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib. Consistent with this model, miR-211 expression increased melanoma cell resistance to both inhibitors…
    DOI:
    10.1016/j.jid.2020.06.038